Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous mesenchymal progenitor stem cells
- Development stage
- Unknown
- Lead developer
- Cima Universidad de Navarra
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraarticular
01
Overview
Autologous mesenchymal progenitor stem cells (MSCs) are an investigational cell therapy consisting of a patient's own multipotent cells, typically harvested from bone marrow or adipose tissue. These cells are processed and expanded ex vivo before being re-administered to the patient, often via intra-articular injection for musculoskeletal conditions. The therapeutic rationale in arthrosis (osteoarthritis) relies on the cells' ability to modulate the local inflammatory environment, secrete regenerative growth factors, and potentially differentiate into chondrocytes to repair damaged cartilage. A specific Phase 2 clinical trial in Spain, conducted by the Clínica Universidad de Navarra, has evaluated these cells in comparison to platelet-rich plasma (PRP) to assess their efficacy in improving joint function and reducing pain in patients with knee osteoarthritis.
- Other names
- autologous mesenchymal stem cellsautologous bone marrow-derived mesenchymal stem cellsautologous mesenchymal progenitor cells
Beyond the preview
Go deeper on autologous mesenchymal progenitor stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous mesenchymal progenitor stem cells.